Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/1311241/000156459019007009/imi-10k_20181231.htm
September 2019
August 2019
July 2019
May 2019
May 2019
February 2019
December 2018
November 2018
August 2018
May 2018
Exhibit 99.1
Intermolecular Reports Fourth Quarter and Full Year 2018 Financial Results
2018 Marked First Full Year of Positive Adjusted EBITDA Since 2013
Positive Operating Cash Flow of $5.9 million in 2018
SAN JOSE, Calif., February 12, 2019 -- Intermolecular, Inc. (Nasdaq: IMI),
the trusted partner for advanced materials innovation, today reported results for the fourth quarter and full year ended December 31, 2018.
Q4 2018 Financial and Operational Highlights
|
• |
Revenue of $6.3 million, which exceeded the company’s guidance. |
|
• |
Program revenue totaled $6.0 million or 95% of total revenue. |
|
• |
Gross profit totaled $4.6 million or 73% of total revenue. |
|
• |
Adjusted EBITDA loss totaled $(1.5) million, which exceeded the company’s guidance. |
|
• |
Net loss totaled $(2.6) million. |
|
• |
Secured two program contracts during the period, including a major new program service agreement with a leading global semiconductor manufacturer. Management expects a material revenue contribution from this customer in 2019. |
Full Year 2018 Financial and Operational Highlights
|
• |
Revenue was $33.7 million. |
|
• |
Program revenue increased 10% to $32.0 million or 95% of total revenue. |
|
• |
Gross profit totaled $23.7 million or 70% of total revenue. |
|
• |
Total operating expenses decreased 22% to $28.0 million. |
|
• |
Adjusted EBITDA improved to $1.8 million compared to a loss of $(0.7) million in 2017. |
|
• |
Net loss improved to $(3.4) million compared to net loss of $(10.4) million in 2017. |
|
• |
Operating cash flow of $5.9 million in 2018. |
|
• |
Cash and investments at December 31, 2018 was $30.4 million (or $0.61 per share), an improvement from $25.8 million (or $0.52 per share) at the end of the prior fiscal year. The company continues to have no debt. |
Management Commentary
“Our performance in 2018 reflected the successful execution of our plan – with $5.9 million of operating cash flow generated by the combination of strong performance with existing customers, commencement of major contracts with new customers, higher gross margins, a reduced cost structure and better working capital management,” said Intermolecular President and CEO Chris Kramer. “While we concluded certain programs to our customers’ satisfaction in 2018 which resulted in a short-term dip in our revenues that will continue in the first quarter of 2019, we retain excellent relationships with each of these customers, and we have secured major new customer programs that position us well for growth going forward.
“We entered 2019 on solid footing with a strong balance sheet and a robust pipeline of business. Following the major new customer we won in late 2018, we secured another contract with a new top tier leading global semiconductor company in the first quarter. With our lower cost structure and higher gross margins, our high throughput services platform now has strong operating leverage which will drive our profitability as we continue to scale our business.”
Fourth Quarter of 2018 Financial Results
Revenue for the fourth quarter of 2018 was $6.3 million, a decrease of 20% from $7.9 million in the third quarter of 2018, and a decrease of 40% from $10.6 million in the same period a year ago. Program revenue was $6.0 million, an 18% decrease from $7.4 million in the third quarter of 2018, and a 32% decrease from $8.9 million in the same period a year ago.
Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/1311241/000156459019007009/imi-10k_20181231.htm
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Intermolecular Inc.
Intermolecular Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:
Rating
Learn More![]()
The decrease in depreciation and amortization expense was due to assets that were fully depreciated.
R&D; costs include personnel-related expenses, including stock-based compensation expenses, for our technical staff as well as consultant costs, parts and prototypes, wafers, chemicals, supply costs, facilities costs, utilities costs related to laboratories and offices occupied by technical staff, depreciation on equipment used by technical staff, long-lived R&D; assets impairment, and outside services, such as machining and third-party R&D; costs.
The changes were primarily attributable to decreases in our personnel-related expenses, professional services fees, and depreciation and amortization expense.
We achieve a higher gross margin on licensing and royalty revenue as compared to program revenue.
We achieve a higher gross margin on licensing and royalty revenue as compared to program revenue.
This increase in gross margin...Read more
We monitor the key financial...Read more
To date, we have financed...Read more
Factors that could cause or...Read more
Stock-based compensation, which was included...Read more
See Note 1 of the...Read more
The changes were attributable to...Read more
The following table presents revenue...Read more
Research and Development R&D; expenses...Read more
Research and Development R&D; expenses...Read more
The following table presents revenue...Read more
Loss from Operations Our operating...Read more
This increase was primarily on...Read more
Our R&D; expenses consist of...Read more
In March 2017, we initiated...Read more
In March 2017, we initiated...Read more
The differences between operating loss...Read more
Program revenue may include service-based...Read more
To date, we have incurred...Read more
In March 2017, we initiated...Read more
General and Administrative General and...Read more
General and Administrative General and...Read more
Our restructuring expense primarily consisted...Read more
In certain instances, minimum license...Read more
Loss from Operations Our operating...Read more
Interest Income (Expense), net The...Read more
Sales and Marketing Sales and...Read more
Sales and Marketing Sales and...Read more
Stock-based compensation, which was included...Read more
Stock-based compensation, which was included...Read more
Stock-based compensation, which was included...Read more
Stock-based compensation, which was included...Read more
Stock-based compensation, which was included...Read more
Stock-based compensation, which was included...Read more
The differences between operating loss...Read more
However, our forecast of the...Read more
These statements are often identified...Read more
Additional funds may not be...Read more
The decrease in personnel-related expenses...Read more
The decrease in personnel-related expenses...Read more
The decrease in personnel-related expenses...Read more
This decrease was primarily attributable...Read more
Different assumptions and judgments would...Read more
Our total revenue decreased to...Read more
In the future, we expect...Read more
Additionally, our cost of revenue...Read more
The changes were primarily attributable...Read more
The changes were primarily attributable...Read more
The changes were primarily attributable...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-K Annual Report
Material Contracts, Statements, Certifications & more
Intermolecular Inc provided additional information to their SEC Filing as exhibits
Ticker: IMI
CIK: 1311241
Form Type: 10-K Annual Report
Accession Number: 0001564590-19-007009
Submitted to the SEC: Fri Mar 08 2019 11:21:43 AM EST
Accepted by the SEC: Fri Mar 08 2019
Period: Monday, December 31, 2018
Industry: Semiconductors And Related Devices